A distinct p53 target gene set predicts for response to the selective p53–HDM2 inhibitor NVP-CGM097

Biomarkers for patient selection are essential for the successful and rapid development of emerging targeted anti-cancer therapeutics. In this study, we report the discovery of a novel patient selection strategy for the p53–HDM2 inhibitor NVP-CGM097, currently under evaluation in clinical trials. By...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeay, Sébastien, Gaulis, Swann, Ferretti, Stéphane, Bitter, Hans, Ito, Moriko, Valat, Thérèse, Murakami, Masato, Ruetz, Stephan, Guthy, Daniel A, Rynn, Caroline, Jensen, Michael R, Wiesmann, Marion, Kallen, Joerg, Furet, Pascal, Gessier, François, Holzer, Philipp, Masuya, Keiichi, Würthner, Jens, Halilovic, Ensar, Hofmann, Francesco, Sellers, William R, Graus Porta, Diana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: eLife Sciences Publications, Ltd 2015
Materias:
Human Biology and Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4468608/
https://www.ncbi.nlm.nih.gov/pubmed/25965177
http://dx.doi.org/10.7554/eLife.06498

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4468608/
https://www.ncbi.nlm.nih.gov/pubmed/25965177
http://dx.doi.org/10.7554/eLife.06498

Ejemplares similares